Patent Due Diligence: Verify Ownership, Chain of Title & Validity

When a deal is built on a patent portfolio, the patents themselves are the asset — and the single most common surprise in diligence is that the company on the term sheet is not the owner of record, or that a key patent is quietly under attack. Patents change hands through assignments, mergers, name changes and security interests, and they can be challenged, narrowed or cancelled at the Patent Trial and Appeal Board. Patent due diligence is the work of confirming that the rights exist, that the seller actually owns them, that no one else has a claim on them, and that they are still in force and unchallenged.

Start with the current owner, not the inventor

A patent lists its inventors, but ownership is a separate question governed by assignments. The first check is the USPTO assignment record: does the chain run cleanly from the inventors, through each employer or acquirer, to the entity selling the patent today? Confirm the recorded assignee matches the deal party exactly — a subsidiary, a holding company, or a predecessor name that was never updated all need to be reconciled before closing.

Assignment chain of title — and the gap analysis

Confirming the current owner is only half the job; the other half is proving the chain of title is unbroken. A clean chain runs, assignment by assignment, from the named inventors to today's owner with no missing link. An assignment gap analysis walks that recorded chain and flags every point where it breaks. The gaps to look for are specific and recurring:

An inventor who never assigned — leaving a co-owner who can independently license the patent. A corporate-transaction gap, where an acquisition transferred the company but the individual patents were never separately assigned to the buyer. A name-change gap, where the entity rebranded or reincorporated and the assignment record still shows the old name. And out-of-order or missing recordations, where an assignment happened but was never recorded at the USPTO, so the public chain simply stops. Each of these clouds title: if the chain doesn't run cleanly to the seller, the seller may not be able to convey what it is promising, and the buyer may inherit a co-owner, a competing claimant, or a patent it can't cleanly enforce.

A good gap analysis doesn't just list the assignments — it reconciles each assignor against the previous assignee, so a break between "who transferred it out" and "who held it before" is caught rather than assumed away. Where a gap exists, it can often be cured (a confirmatory or nunc pro tunc assignment), but only if it is found before closing.

Encumbrances: who else has a claim?

Patents are collateral. Security interests, liens and prior licenses are frequently recorded against them, and an exclusive license granted years ago can hollow out the value of a patent the seller still "owns." Search the assignment database for security interests and confirm whether any have been released. Undisclosed licenses — especially exclusive ones — are among the most damaging findings because they limit what the buyer can do with the asset regardless of who holds title.

PTAB due diligence: is the patent under challenge?

Ownership means little if the patent is invalid or being cut down — and since the America Invents Act, the fastest way that happens is at the Patent Trial and Appeal Board (PTAB). The PTAB hears administrative challenges to issued patents, and a patent caught up in one is a very different asset from a clean grant. PTAB diligence means checking, for every patent that matters, whether it has been challenged, what kind of proceeding it faced, and how it came out.

The proceedings to know are inter partes review (IPR), the most common, where a challenger argues the claims were anticipated or obvious over prior art; post-grant review (PGR), a broader challenge available only in a patent's first nine months; and the now-sunset covered-business-method (CBM) review you may still see in older records. What matters for diligence is the status and outcome, not just the existence of a filing. Was the petition instituted (the Board found it worth hearing) or denied? If instituted, did the final written decision uphold the claims, cancel some, or cancel all of them? Were claims amended during the proceeding, narrowing their scope? A patent whose key claims were cancelled may be worth little; one that was challenged and survived is battle-tested and arguably stronger.

Two further points sharpen the picture. A pending IPR is an open risk — the claims could still be cancelled — and should be treated as a live contingency, not a footnote. And IPR carries estoppel: a challenger who loses generally can't re-raise the same grounds in court, which affects how durable a survived patent really is. Reading the PTAB record properly turns "is this patent valid?" from a guess into an evidenced answer.

Litigation on the record

Patent litigation is a related signal, and some of it surfaces on the patent record itself: under 35 U.S.C. § 290, courts must notify the USPTO of patent infringement suits, and those notices appear in the file history. A patent that has been asserted and survived is battle-tested; one that was asserted and lost, or is entangled in ongoing litigation, is a different risk. Cross-checking federal court records for the patent and its owner completes the validity-and-enforcement view.

Is the patent still alive?

A granted patent is not a permanent right. U.S. utility patents require maintenance fees at 3.5, 7.5 and 11.5 years; miss one and the patent lapses, sometimes irreversibly. Check the maintenance-fee status and the next deadline for every patent that matters — a portfolio with several fees coming due carries a quiet cost the buyer will inherit, and a lapsed patent still listed as an asset is a finding in its own right. Expiration is the other half of the lifecycle: a patent near the end of its 20-year term from filing may have little enforcement value left, however impressive it looks on a list.

The worldwide family

Most valuable inventions are protected in more than one country. A U.S. patent is often the anchor of a family filed through the PCT and prosecuted at the EPO and in Japan, Korea and China. Map the family before you value the portfolio: coverage that stops at the U.S. border is a real limitation for a company that sells globally, and foreign counterparts have their own renewal deadlines and legal status that must be checked jurisdiction by jurisdiction.

From verification to freedom to operate

Confirming ownership, a clean chain, no encumbrances, and unchallenged validity tells you the seller has something real to sell. It does not tell you the buyer is free to practice the invention — that is a separate freedom-to-operate analysis against third-party patents, and it belongs on any thorough IP diligence plan. Use the public record to establish title, gaps, PTAB status and encumbrances first; it answers most of the questions that actually kill deals. This is general information, not legal advice; patent matters are fact-specific and jurisdictional.